MA47816A - Composition pharmaceutique comprenant du sélexipag - Google Patents

Composition pharmaceutique comprenant du sélexipag

Info

Publication number
MA47816A
MA47816A MA047816A MA47816A MA47816A MA 47816 A MA47816 A MA 47816A MA 047816 A MA047816 A MA 047816A MA 47816 A MA47816 A MA 47816A MA 47816 A MA47816 A MA 47816A
Authority
MA
Morocco
Prior art keywords
selexipag
pharmaceutical composition
composition consisting
pharmaceutical
composition
Prior art date
Application number
MA047816A
Other languages
English (en)
Inventor
Klaus Hellerbrand
Alexandra Schlicker-Spain
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61655736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA47816(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA47816A publication Critical patent/MA47816A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA047816A 2017-03-08 2018-03-07 Composition pharmaceutique comprenant du sélexipag MA47816A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2017055406 2017-03-08

Publications (1)

Publication Number Publication Date
MA47816A true MA47816A (fr) 2020-01-15

Family

ID=61655736

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047816A MA47816A (fr) 2017-03-08 2018-03-07 Composition pharmaceutique comprenant du sélexipag

Country Status (27)

Country Link
US (1) US12121516B2 (fr)
EP (1) EP3592391B1 (fr)
JP (1) JP6964679B2 (fr)
KR (1) KR102593075B1 (fr)
CN (1) CN110430900B (fr)
AR (1) AR111570A1 (fr)
AU (1) AU2018229750B2 (fr)
BR (1) BR112019018420A2 (fr)
CA (1) CA3055010A1 (fr)
CL (1) CL2019002511A1 (fr)
CO (1) CO2019009221A2 (fr)
CR (1) CR20190455A (fr)
DO (1) DOP2019000250A (fr)
EA (1) EA201992074A1 (fr)
EC (1) ECSP19072294A (fr)
ES (1) ES2880009T3 (fr)
IL (1) IL269061A (fr)
JO (1) JOP20190204A1 (fr)
MA (1) MA47816A (fr)
MX (1) MX391339B (fr)
NI (1) NI201900090A (fr)
PE (1) PE20191492A1 (fr)
PH (1) PH12019502033A1 (fr)
PL (1) PL3592391T3 (fr)
SG (1) SG11201907804QA (fr)
TW (1) TWI764996B (fr)
WO (1) WO2018162527A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532076A (ja) * 2019-05-06 2022-07-13 アクテリオン ファーマシューティカルズ リミテッド サルコイドーシス関連肺高血圧症の治療方法
WO2020249602A1 (fr) * 2019-06-11 2020-12-17 Actelion Pharmaceuticals Ltd Procédés de traitement de l'hypertension artérielle pulmonaire
PH12022550937A1 (en) 2019-10-23 2023-06-14 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising selexipag
US20230113077A1 (en) 2020-01-31 2023-04-13 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
TW202239408A (zh) * 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
WO2022215045A1 (fr) * 2021-04-08 2022-10-13 Glenmark Pharmaceutical Limited Composition lyophilisée comprenant du sélexipag
WO2023131608A1 (fr) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Compositions à libération contrôlée
WO2023209731A1 (fr) * 2022-04-25 2023-11-02 Msn Laboratories Private Limited, R&D Center Formes posologiques injectables liquides ou lyophilisées de sélexipag et leur procédé de préparation
WO2023214059A1 (fr) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Composés de diphénylpyrazine utilisés en tant que promédicaments
JP2025114012A (ja) * 2022-06-10 2025-08-05 日本新薬株式会社 持続型注射剤
WO2024017964A1 (fr) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Composition pharmaceutique injectable comprenant un dérivé de diphénylpyrazine
WO2024133620A1 (fr) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd Test de dissolution in vitro
WO2024194449A1 (fr) 2023-03-23 2024-09-26 Actelion Pharmaceuticals Ltd Composition pharmaceutique comprenant un dérivé de diphénylpyrazine
WO2025009945A1 (fr) * 2023-07-06 2025-01-09 재단법인대구경북과학기술원 Composition pharmaceutique pour la prévention ou le traitement de maladies cérébrales dégénératives comprenant du sélexipag
EP4595961A1 (fr) * 2024-02-01 2025-08-06 Sorbonne Universite Selexipag pour utilisation dans le traitement et/ou la prévention de l'athérosclérose
WO2025196095A1 (fr) 2024-03-20 2025-09-25 Actelion Pharmaceuticals Ltd Composition pharmaceutique injectable pour le traitement de l'hypertension pulmonaire

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (fr) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
ATE397440T1 (de) * 2002-02-22 2008-06-15 Schering Corp Pharmazeutische zubereitungen von antineoplastischen wirkstoffen, insbesondere temozolomid, verfahren zu ihrer herstellung und deren verwendung
ES2817557T3 (es) 2008-02-28 2021-04-07 Nippon Shinyaku Co Ltd Inhibidor de fibrosis
WO2009154246A1 (fr) 2008-06-19 2009-12-23 日本新薬株式会社 Agent thérapeutique pour un dysfonctionnement érectile
CN102065864B (zh) 2008-06-23 2012-11-21 日本新药株式会社 炎性肠病治疗剂
WO2009157397A1 (fr) 2008-06-23 2009-12-30 日本新薬株式会社 Agent thérapeutique pour une lésion au tractus intestinal accompagnant l’administration d’un anti-inflammatoire nonstéroïdien
PL2292231T3 (pl) 2008-06-23 2016-03-31 Nippon Shinyaku Co Ltd Środek terapeutyczny przeciw zwężeniu kanału kręgowego
MX346318B (es) 2009-06-26 2017-03-15 Nippon Shinyaku Co Ltd Cristales.
WO2011024874A1 (fr) 2009-08-26 2011-03-03 日本新薬株式会社 Sels d'addition avec une base
BR112013027009A2 (pt) * 2011-04-19 2016-12-27 Rigshospitalet prostaciclina e análogos da mesa administrada durante cirurgia para prevenção e tratamento de derrame capilar
US9872864B2 (en) 2011-08-12 2018-01-23 Ascendis Pharma A/S Sustained release composition of prostacyclin
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
GB201400412D0 (en) * 2014-01-10 2014-02-26 Heart Biotech Ltd Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
WO2017029594A1 (fr) * 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Procédés de préparation de selexipag et de sa forme amorphe
WO2017040872A1 (fr) * 2015-09-03 2017-03-09 Teva Pharmaceuticals International Gmbh Formes à l'état solide de selexipag
DK4331607T3 (da) 2015-12-02 2025-05-19 Nippon Shinyaku Co Ltd Fast farmaceutisk sammensætning indeholdende 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamid
EP3192502A1 (fr) 2016-01-15 2017-07-19 Sandoz Ag Composition pharmaceutique de selexipag

Also Published As

Publication number Publication date
JP2020509070A (ja) 2020-03-26
PL3592391T3 (pl) 2021-11-02
NI201900090A (es) 2020-03-11
MX391339B (es) 2025-03-21
JP6964679B2 (ja) 2021-11-10
JOP20190204A1 (ar) 2019-09-05
EA201992074A1 (ru) 2020-02-27
AR111570A1 (es) 2019-07-31
EP3592391B1 (fr) 2021-04-21
KR102593075B1 (ko) 2023-10-23
CR20190455A (es) 2019-11-12
BR112019018420A2 (pt) 2020-04-14
CA3055010A1 (fr) 2018-09-13
US12121516B2 (en) 2024-10-22
PH12019502033A1 (en) 2020-06-15
PE20191492A1 (es) 2019-10-21
TWI764996B (zh) 2022-05-21
KR20190122803A (ko) 2019-10-30
WO2018162527A1 (fr) 2018-09-13
CO2019009221A2 (es) 2019-08-30
AU2018229750B2 (en) 2023-11-23
TW201842910A (zh) 2018-12-16
ECSP19072294A (es) 2019-11-30
CL2019002511A1 (es) 2020-01-17
ES2880009T3 (es) 2021-11-23
EP3592391A1 (fr) 2020-01-15
US20200129506A1 (en) 2020-04-30
IL269061A (en) 2019-11-28
MX2019010598A (es) 2019-10-15
SG11201907804QA (en) 2019-09-27
DOP2019000250A (es) 2020-09-15
AU2018229750A1 (en) 2019-09-12
CN110430900A (zh) 2019-11-08
CN110430900B (zh) 2023-09-19

Similar Documents

Publication Publication Date Title
EP3493799A4 (fr) Composition pharmaceutique decannabis
EP3493798A4 (fr) Composition pharmaceutique decannabis
MA46334A (fr) Composition pharmaceutique liquide
DK3655038T3 (da) Farmaceutisk sammensætning
EP3452075A4 (fr) Composition pharmaceutique ophtalmique
MA43705A (fr) Formulation pharmaceutique
DK3532029T3 (da) Flydende farmaceutisk sammensætning
EP3679945A4 (fr) Composition pharmaceutique aqueuse
EP3412660A4 (fr) Dérivé de sulfonamide et composition pharmaceutique le contenant
EP3685828A4 (fr) Composition pharmaceutique ophtalmique, trousse ophtalmique et application pharmaceutique associée
EP3429589A4 (fr) Composition pharmaceutique du nilotinib
DK3672631T3 (da) Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
DK3634377T3 (da) Farmaceutisk formulering
EP3689892A4 (fr) Médicament radioactif
MA47516A (fr) Composition pharmaceutique
EP3402470A4 (fr) Composition pharmaceutique stable
EP3323413A4 (fr) Composition pharmaceutique contenant du célécoxib et du tramadol
EP3582759A4 (fr) Composition pharmaceutique bioéquivalente de bromhydrate de vortioxétine
EP3459369A4 (fr) Composition pharmaceutique utilisant la souchelactobacillus
EP3646866A4 (fr) Préparation pharmaceutique
MA49822A (fr) Combinaison pharmaceutique comprenant du ponesimod
MA49837A (fr) Compositions pharmaceutiques
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
EP3646867A4 (fr) Composition pharmaceutique
EP3646863A4 (fr) Composition pharmaceutique